Impax says Parkinson’s disease treatment is safe, effective
HAYWARD, Calif. — An investigational drug for Parkinson’s disease was safe and effective, according to results of a late-stage clinical trial scheduled for presentation next week.
Impax Pharmaceuticals, the branded products division of Impax Labs, said it would present data from a phase-3 trial of extended-release IPX066 (carbidopa-levodopa) at the American Academy of Neurology Conference’s annual meeting in Hawaii, which takes place from April 9 through April 16.
The company also said there were no unexpected serious side effects observed in patients.
Watson receives FDA approval for Nulecit
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for iron deficiency anemia made by Watson Pharmaceuticals, Watson said Thursday.
The drug maker announced the approval of Nulecit (sodium ferric gluconate complex in sucrose), an injectable and generic version of Sanofi-Aventis’ Ferrlecit.
The drug is used to treat iron deficiency anemia in adults and children ages 6 years and older undergoing chronic hemodialysis and receiving supplemental epoetin therapy.
DDF develops calendar of events to prevent diabetes, complications
MADEIRA BEACH, Fla. — A nonprofit charity that focuses on diabetes prevention efforts announced the launch of a calendar of events on its website, in line with what has been designated as Defeat Diabetes Month.
The Defeat Diabetes Foundation said that the calendar is designed to empower families with tools to prevent diabetes or related complications. The calendar also provides links to articles, downloads, tools, puzzles and games, nutrition tips, healthy recipes and more.
"We are providing information and activities focused on getting you to live just a little bit healthier each and every day," said Andrew Mandell, executive director of DDF. "People know that many of their eating and/or exercise habits are bad for their health, but they aren’t sure how to break them. Defeat Diabetes Month is a great way to start."